Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Male or non-pregnant female subjects50 years of age and older with a 6-month history of OA of the knee~2. Female subjects were eligible for participation in the study if they were of non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or of childbearing potential, had a negative pregnancy test at Screening, and using adequate contraceptive methods.~3. Subjects were required to have been on a stable dose of NSAIDs, COX-2 inhibitors or other oral analgesic therapy for at least 6 weeks and required to continue treatment for 12 weeks. Current oral analgesic therapy was withdrawn at Screening.~4. Each subject was required to be able to understand and comply with study procedures required of a subject and was able and willing to provide written informed consent prior to any study procedures being performed.~5. Subjects were required to agree to keep physical activity at a stable level throughout the study.~6. Subjects were required to have symptomatic OA of the knee meeting American College of Rheumatology (ACR) criteria for clinical diagnosis of OA.~7. Subjects were required to have an ACR functional class rating of I, II or III. In addition, subjects meet the requirements for OA flare at the Baseline/ Randomization Visit.~Exclusion Criteria~1. Subjects with rheumatoid arthritis or gout/pseudo-gout~2. Subjects with fibromyalgia syndrome~3. Acute joint trauma at the index joint within the 3 months prior to screen with active symptoms~4. Previous (in the past 12 months) or anticipated need for surgical or invasive procedure performed on the index joint during the study~5. Subject was currently taking or anticipated to take Coumadin®, warfarin, or lithium~6. History of hypersensitivity to esomeprazole or to another PPI~7. History of allergic reaction or intolerance to any NSAID (including aspirin) and/or subject had a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps~8. History of allergic reactions to sulfonamides~9. Subjects with intra-articular or intramuscular corticosteroids or intra-articular hyaluronic acid injections within 8 weeks prior to randomization~10. Participation in any study of an investigational treatment in the 4 weeks before Screening~11. Presence of uncontrolled acute or chronic medical illness, e.g. morbid obesity, GI disorder, diabetes, active GI disease, chronic or acute renal or hepatic disorder, depression and/or infection, etc, that would endanger a subject if the subject were to participate in the study~12. GI disorder (e.g., severe erosive esophagitis, Zollinger Ellison syndrome) or surgery leading to impaired drug absorption~13. Peptic ulcer disease within 6 months prior to Screening~14. Evidence of uncontrolled, or unstable cardio- or cerebrovascular disorder, which in the investigator's opinion would have endangered a subject if the subject were to participate in the study~15. Schizophrenia or bipolar disorder~16. Subjects who had started physical therapy on the index joint less than 6 weeks prior to study Screening~17. Use of any excluded concomitant medication~18. A recent history (in the past 3 months) suggestive of alcohol or drug abuse or dependence, including overuse/abuse of narcotics for management of pain~19. Serious blood coagulation disorder including use of systemic anti-coagulants~20. Screening laboratory value for alanine aminotransferase, aspartate aminotransferase greater than 2 times the upper limit of normal~21. Estimated creatinine clearance less than 30 ml/min~22. Other than noted specifically, any Screening laboratory value that was clinically significant in the investigator's opinion and would have endangered a subject if the subjects were to participate in the study~23. History of malignancy, treated or untreated, within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin~24. Previous participation in another PN 400 clinical research trial~25. Subjects who were employees of the research facility or who were in some way under the supervision of the principal investigator for this study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 PN 400 (VIMOVO) (Type: EXPERIMENTAL): PN400: 500 mg naproxen/20 mg esomeprazole bid
- Arm 2 (Celebrex) (Type: ACTIVE_COMPARATOR): Celecoxib 200 mg
- Arm 3 (Placebo) (Type: PLACEBO_COMPARATOR): sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).